Abstract
Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Current Pharmaceutical Design
Title: What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?
Volume: 16 Issue: 14
Author(s): Burkhard Goke
Affiliation:
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Abstract: Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Export Options
About this article
Cite this article as:
Goke Burkhard, What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164081
DOI https://dx.doi.org/10.2174/138161210791164081 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Mammalian Target of Rapamycin in Atherosclerosis
Current Molecular Medicine Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling
Current Drug Discovery Technologies Diabetic Bone Fracture Repair: A Progenitor Cell-Based Paradigm
Current Stem Cell Research & Therapy Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry A Genome-wide Association Analysis in Four Populations Reveals Strong Genetic Heterogeneity For Birth Weight
Current Genomics Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics
Drug Metabolism Letters Characterization of Optimized Functional-Complementary Dual Insulinotorpic Peptide rolGG
Current Pharmaceutical Biotechnology Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives
Current Diabetes Reviews Editorial [Hot Topic: Nitric Oxide and Hydrogen Sulfide - Contribution of Gaseous Messengers to the Cardiovascular Control (Guest Editor: Sona Cacanyiova)]
Current Pharmaceutical Biotechnology DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Current Diabetes Reviews Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies A Comprehensive Review on Recent advances in Synthesis & Pharmacotherapeutic potential of Benzothiazoles
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology